Immunitybio, Inc.

This phase 3 trial tests whether adding an experimental drug (N-803) to standard chemotherapy (docetaxel) can help people with advanced non-small cell lung cancer whose disease has stopped responding to immunotherapy. About 507 participants will be randomly assigned to receive ei…

This study tests a new combination of drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors and improve survival. Particip…

This study tests a new genetically modified version of the BCG vaccine (rMBCG) given directly into the bladder for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The goal is to see if it is safe and can control the cancer. About 40 adults…

This early-phase study tests a new treatment called CD19 t-haNK, a type of immune cell designed to attack lymphoma cells. It is given alone or with two other drugs (N-803 and rituximab) to up to 20 adults whose Non-Hodgkin lymphoma has returned or not responded to at least two pr…

This study tests a combination of drugs (nogapendekin alfa inbakicept, bevacizumab, and immune cells) with or without tumor treatment fields in people whose glioblastoma has returned or worsened. The goal is to see if these treatments can safely control the cancer and improve sur…

This early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…

This study tests the safety of a drug called Anktiva (NAI) in 40 adults with Long COVID—symptoms that last long after a COVID-19 infection is over. Researchers will monitor side effects and check if the drug helps reduce symptoms. The goal is to find a safe treatment for this lin…

This study provides expanded access to an experimental drug called nogapendekin-alfa inbakicept for adults with low lymphocyte counts (lymphopenia) caused by chemotherapy, immunotherapy, or radiation therapy. The goal is to restore and maintain healthy lymphocyte levels. Particip…

This study tests a new treatment for people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based chemotherapy. The treatment uses a person's own immune cells (called natural killer cells) that are boosted in a lab and given back along with a drug…

This program provides a new type of BCG treatment (rMBCG) to people with non-muscle invasive bladder cancer who cannot take part in a clinical trial. It is for patients who would normally receive standard BCG therapy but cannot access it. The goal is to offer a potential treatmen…

This early-phase study tests a new treatment called CD19 t-haNK, a type of immune cell that targets cancer, alone or with the drug rituximab. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are …

This study tests whether a drug called Anktiva is safe and tolerable for people with Long COVID. About 20 adults aged 18 to 69 who have had COVID-19 will receive up to two doses. Researchers will monitor side effects and check if symptoms improve using questionnaires.